Skip to main content

Table 3 The biomarker levels in the two categories (HS/NHS) of patients

From: Serological biomarker testing helps avoiding unnecessary endoscopies in obese patients before bariatric surgery

 

Whole Series

Healthy stomach (HS Group)

n = 22

Non-healthy stomach (NHS Group)

n = 43

(p-value)#

aG17b pmol/l mean ± SD (range)

3.9 ± 5.0

(0–28.1)

2.05 ± 2.2

(0–9.9)

4.9 ± 5.7

(0–28.1)

0.028

bG17 s pmol/l mean ± SD (range)

12.3 ± 10.3

(0–40.9)

8.8 ± 8.4

(0.2–36.1)

14.1 ± 10.8

(0–40.9)

0.048

PG I μg/I mean ± SD (range)

81.8 ± 38.6

(22.7–197.5)

58.2 ± 27.9

(33.0–151.1)

93.9 ± 38.0

(22.7–197.5)

< 0.0001

PG II μg/I mean ± SD (range)

7.2 ± 5.9

(0.3–29.3)

3.37 ± 1.7

(0.3–8.4)

9.2 ± 6.4

(1.4–29.3)

< 0.0001

PG I/PG II mean ± SD (range)

15.5 ± 12.3

(3.3–103.3)

21.6 ± 18.9

(10.7–103.3)

12.4 ± 4.6

(3.2–25.2)

< 0.0001

IgG EIU mean ± SD (range)

64.2 ± 40.8

(2.1–121.1)

13.12 ± 7.7

(2.1–27.3)

90.4 ± 21.1

(38.1–121.1)

< 0.0001

  1. a G-17b, basal gastrin-17
  2. b G-17 s, stimulated gastrin-17
  3. #Mann-Whitney U-Test